Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats

Brain Research

Volumn 800, Issue 2, 1998, Pages 260-268

  Wei, D ^a   Maisonneuve, I M ^a   Kuehne, M E ^b   Glick, S D ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

18 Methoxycoronaridine; Ibogaine; In vivo microdialysis; Noribogaine; Nucleus accumbens; Rat; Serotonin; Striatum

Indexed keywords

18 METHOXYCORONARIDINE; CORONARIDINE; IBOGAINE; NORIBOGAINE; SEROTONIN; SEROTONIN TRANSPORTER; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADDICTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM;

ANIMALS; CORPUS STRIATUM; EXTRACELLULAR SPACE; FEMALE; HALLUCINOGENS; IBOGAINE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICRODIALYSIS; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 0032479991     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00527-7     Document Type: Article

References (64)

1. Aronson S.C., Black J.E., McDougle C.J., Scanley B.E., Jatlow P., Kosten T.R., Heninger G.R., Price L.H. Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology. 119:1995;179-185.
2. Badio B., Padgett W.L., Daly J.W. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol. Pharmacol. 51:1997;1-5.
3. Battaglia G., Yeh S.Y., De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29:1988;269-274.
4. Berger U.V., Grzanna R., Molliver M.E. The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin. Brain Res. 578:1992;177-185.
5. Broderick P.A., Phelan F.T., Eng F., Wechsler R.T. Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies. Pharmacol. Biochem. Behav. 49:1994;711-728.
6. Cappendijk S.L.T., Dzoljic M.R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol. 241:1993;261-265.
7. Deecher D.C., Teitler M., Soderlund D.M., Bornmann W.G., Kuehne M.E., Glick S.D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 571:1992;242-247.
8. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D. Jr., Ashby C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15:1995;821-829.
9. Fiorella D., Rabin R.A., Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs: I. Antagonist correlation analysis. Psychopharmacology. 121:1995;347-356.
10. Fuller R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 55:1994;163-167.
11. E.L. Gardner, Brain reward mechanisms, in: J.H. Lowinson, P. Ruiz, R.B. Millman (Eds.), Substance Abuse: A Comprehensive Textbook, 2nd edn., Willams & Wilkins, 1992, pp. 70-99.
12. Glick S.D., Pearl S.M., Cai J., Maisonneuve I.M. Ibogaine-like effects of noribogaine in rats. Brain Res. 713:1996;294-297.
13. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., Molinari H.H. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res. 719:1996;29-35.
14. Glick S.D., Kuehne M.E., Raucci J., Wilson T.E., Larson D., Keller R.W. Jr., Carlson J.N. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 657:1994;14-22.
15. Glick S.D., Rossman K., Rao N.C., Maisonneuve I.M., Carlson J.N. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology. 31:1992;497-500.
16. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
17. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66:1996;243-249.
18. Gundlah C., Martin K.F., Heal D.J., Auerbach S.B. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J. Pharmacol. Exp. Ther. 283:1997;581-591.
19. Hekmatpanah C.R., Peroutka S.J. 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur. J. Pharmacol. 177:1990;95-100.
20. Higgins G.A., Wang Y., Sellers E.M. Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-administration in rats. Pharmacol. Biochem. Behav. 45:1993;963-966.
21. Hyman S.E. Addiction to cocaine and amphetamine. Neuron. 16:1996;901-904.
22. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 12:1992;165-219.
23. Jacobs B.L. An animal behavior model for studying central serotonergic synapses. Life Sci. 19:1976;777-786.
24. James T.A., Starr M.S. Rotational behavior elicited by 5-HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J. Pharm. Pharmacol. 32:1980;196-200.
25. Joseph R., Tsering C., Grunfeld S., Welch K.M. Serotonin may have neurotoxic properties. Neurosci. Lett. 136:1992;15-18.
26. Kelland M.D., Freeman A.S., Chiodo L.A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Exp. Ther. 253:1990;803-811.
27. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. TIPS. 13:1992;177-184.
28. Loh E.A., Roberts D.C.S. Break-points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology. 101:1990;262-266.
29. H.S. Lotsof, Rapid method for interrupting the narcotic addiction syndrome, U.S. Patent No. 4,499,096, 1985.
30. H.S. Lotsof, Rapid method for interrupting the cocaine and amphetamine abuse syndrome, U.S. Patent No. 4,587,243, 1986.
31. H.S. Lotsof, Rapid method for attenuating the alcohol dependency syndrome, U.S. Patent No. 4,857,523, 1989.
32. H.S. Lotsof, Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, U.S. Patent No. 5,026,697, 1991.
33. H.S. Lotsof, Rapid method for interrupting or attenuating poly-drug dependency syndromes, U.S. Patent No. 5,152,994, 1992.
34. Lotsof H.S. Ibogaine in the treatment of chemical dependence disorders: clinical perspectives. MAPS. 5:1995;16-27.
35. Mach R.H., Smith C.R., Childers S.R. Ibogaine possesses a selective affinity for sigma 2 receptors. Life Sci. 57:1995;PL57-PL62.
36. Maisonneuve I.M., Rossman K.L., Keller R.W., Glick S.D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 575:1992;69-73.
37. Mash D.C., Staley J.K., Baumann M.H., Rothman R.B., Hearn W.L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 57:1995;PL45-50.
38. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
39. Miller N.S. Pharmacotherapy in alcoholism. J. Addictive Dis. 14:1995;23-46.
40. Molinari H.H., Maisonneuve I.M., Glick S.D. Ibogaine neurotoxicity: a re-evaluation. Brain Res. 737:1996;255-262.
41. O'Hearn E., Molliver M.E. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience. 55:1993;303-310.
42. Palumbo P.A., Winter J.C. Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD. Pharmacol. Biochem. Behav. 92:1992;1221-1226.
43. Parsons L.H., Koob G.F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J. Pharmacol. Exp. Ther. 274:1995;1182-1191.
44. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, Orlando, FL, 1996.
45. Phelix C.F., Broderick P.A. Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res. Bull. 37:1995;37-40.
46. Popik P., Layer R.T., Fossom L.H., Benveniste M., Geter-Douglass B., Witkin J.M., Skolnick P. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:1995;753-760.
47. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology (Berlin). 114:1994;672-674.
48. Rezvani A.H., Mash D., Overstreet D.H., Hearn W.L., Lee Y.W. Suppressing effect of 12-hydroxyibogamine, the primary metabolite of ibogaine, on alcohol intake in rats. Alcohol Clin. Exp. Res. 19:1995;15A.
49. Rezvani A.H., Overstreet D.H., Lee Y.W. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol. Biochem. Behav. 52:1995;615-620.
50. Rezvani A.H., Overstreet D.H., Yang Y., Maisonneuve I.M., Bandarage U.K., Kuehne M.E., Glick S.D. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol. Biochem. Behav. 58:1997;615-619.
51. Richardson N.R., Roberts D.C.S. Fluoxetine pre-treatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci. 49:1991;833-840.
52. Satel S.L., Krystal J.K., Delgado P.L., Kosten T.R., Charney D.S. Tryptophan depletion and attenuation of cue-induced craving for cocaine. Am. J. Psychiatry. 152:1995;778-783.
53. Schechter M.D., Gordon T.L. Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity. Eur. J. Pharmacol. 249:1993;79-84.
54. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240:1987;1-7.
55. Smith J.E., Shultz K., Co C., Goeders N.E., Dworkin S.I. Effects of 5,7-dihydroxytryptamine lesions of the nucleus accumbens on intravenous morphine self-administration. Pharmacol. Biochem. Behav. 26:1987;607-612.
56. Spealman R.D. Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology. 112:1993;93-99.
57. Spyraki C., Nomikos G.G., Galanopoulou P., Daifotis Z. Drug-induced place preference in rats with 5,7-dihydroxytryptamine lesions of the nucleus accumbens. Behav. Brain Res. 29:1988;127-134.
58. Steinbusch H.W.M. Distribution of serotonin-immunoreactivity in the central nervous system of the rat - cell bodies and terminals. Neuroscience. 4:1981;557-618.
59. Sweetnam P.M., Lancaster J., Snowman A., Collins J.L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology (Berlin). 118:1995;369-376.
60. Teitler M., Lyon R.A., Glennon R.A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
61. Ugedo L., Grenhoff J., Svensson T.H. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berlin). 98:1989;45-50.
62. van der Kooy D., Hattori T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res. 186:1980;1-7.
63. White F.J. Synaptic regulation of mesocorticolimbic dopamine neurons. Annu. Rev. Neurosci. 19:1996;405-436.
64. Zetler G., Singbarth G., Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology. 7:1972;237-248.